India’s 2nd Largest Animal Health Company – Zenex Animal Health India Pvt. Ltd. has taken center stage in private equity and market discussions this month as the company accelerates its preparations for a highly anticipated Initial Public Offering (IPO).
Backed by Multiples Private Equity and RARE – a well knwon stock market investment firm, Zenex—formerly the animal health division of pharma giant Zydus Cadila—is positioning itself to capitalize on the rapidly expanding global and domestic veterinary healthcare markets. Presence of RARE’s nominee on Zenex’s board had ensured an IPO route, sooner rather than later. Zenex could be yet another listed Animal Health companies like Viyash (formerly Sequent Scientific), Hester Biosciences and NGL Fine Chemicals.
From Corporate Division to Independent Powerhouse
Zenex’s journey to the public markets highlights a successful corporate carve-out strategy. In 2021, a consortium led by Multiples Private Equity acquired Zydus Animal Health and Investments Limited for ₹2,921 Crore, rebranding the entity as Zenex.
Since the acquisition, Zenex has evolved from a domestic corporate division into a streamlined, independent multinational player. The company holds a dominant position in the Indian livestock and poultry healthcare segments, leveraging a robust portfolio of:
-
Therapeutics and Vaccines: Advanced biologicals (through in-licensing) protecting commercial poultry and cattle herds
-
Nutritional Supplements: High-margin additives designed to optimize livestock productivity
Financial Positioning and Strategic Optimizations
In the lead-up to the IPO, Zenex has focused heavily on twin strategies of Bolt-on acquisitions, internal margin optimization and structural efficiency which is expected to continue under the leadership of its recently appointed Chief Executive Officer, Aniruddha Rajurkar.
Key Market Performance Metrics:
-
Margin Enhancement: While domestic top-line revenue growth has shown mild deceleration due to high market saturation in standard segments, Zenex has successfully driven significant improvements in its core operating margins and overall profitability through portfolio and geographical mix
-
Global Footprint Expansion: A key value driver for institutional investors is Zenex’s recent majority-stake acquisition of European animal nutrition firm Vievepharm. This cross-border transaction allows Zenex to immediately scale its therapeutic distribution network into premium international markets
Private Equity Sentiment and Market Outlook
The upcoming IPO is being closely watched by institutional investors as a bellwether for the Indian animal health sector. The pet care and livestock therapeutics industry has seen a massive surge in post-pandemic valuation, driven by increased awareness of zoonotic biosecurity and the premiumization of companion animal care.
Strategic Takeaway for Investors
Zenex’s public listing represents a growing trend of private equity-backed animal health platforms seeking public capital to fund next-generation R&D. By shifting its focus toward high-margin therapeutics and expanding its global footprint, Zenex offers a compelling value proposition for investors looking for recession-resistant assets in the broader healthcare stack.
